Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2015

Open Access 01-12-2015 | Research article

Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning

Authors: K. O’Sullivan, F. Boland, U. Reulbach, N. Motterlini, D. Kelly, K. Bennett, T. Fahey

Published in: BMC Pediatrics | Issue 1/2015

Login to get access

Abstract

Background

In 2003, the Irish Medicines Board (IMB) warned against the treatment of childhood depression with selective serotonin reuptake inhibitors (SSRIs) due to increased risk of suicide. This study examined the effect of this warning on the prevalence of anti-depressants in Irish children and compared age and gender trends and international comparisons of prescription rates.

Methods

A retrospective cohort study of the Irish Health Service Executive (HSE) pharmacy claims database for the General Medical Services (GMS) scheme for dispensed medication. Data were obtained for 2002–2011 for those aged ≤15 years. Prevalence of anti-depressants per 1000 eligible population, along with 95 % confidence intervals, were calculated. A negative binomial regression analysis was used to investigate trends and compare rates across years, sex and age groups (0–4, 5–11, 12–15 years). International prescribing data were retrieved from the literature.

Results

The prevalence of anti-depressants decreased from 4.74/1000 population (95 % CI: 4.47-5.01) in 2002 to 2.61/1000 population (95 % CI: 2.43-2.80) in 2008. SSRI rates decreased from 2002 to 2008. Prescription rates for contra-indicated SSRIs paroxetine, sertraline and citralopram decreased significantly from 2002 to 2005, and, apart from paroxetine, only small fluctuations were seen from 2005 onwards. Fluoxetine was the most frequently prescribed anti-depressant and rates increased between 2002 and 2011. Anti-depressant rates were higher for younger boys and older girls. The Irish prevalence was lower than the US, similar to the U.K. and higher than Germany and Denmark.

Conclusions

The direction and timing of these trends suggest that medical practitioners followed the IMB advice.
Literature
1.
2.
Kessler RC, Chiu W, Demler O, Walters EE. PRevalence, severity, and comorbidity of 12-month dsm-iv disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):617–27.CrossRefPubMedPubMedCentral
3.
Cheung AH, Emslie GJ, Mayes TL. The use of anti-depressants to treat depression in children and adolescents. Can Med Assoc J. 2006;174(2):193–200.CrossRef
4.
5.
Jane Costello E, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychology and Psychiatry. 2006;47(12):1263–71.
6.
Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol. 2006;16(3):273–85. PubMed Epub 2006/06/14. eng.CrossRefPubMed
7.
Murray ML, de Vries CS, Wong ICK. A drug utilisation study of anti-depressants in children and adolescents using the general practice research database. Arch Dis Child. 2004;89(12):1098–102.CrossRefPubMedPubMedCentral
8.
9.
Zito J, Tobi H, de Jong-van den L, Fegert J, Safer D, Janhsen K, et al. Anti-depressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006;15:793–8. doi:10.​1002/​pds.​1254. PubMed PMID.CrossRefPubMed
10.
Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998;159:1245–52.PubMedPubMedCentral
11.
Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Academy of Child & Adolescent Psychiatry. 2001;40(7):762–72.CrossRef
12.
Wijlaars LPMM, Nazareth I, Petersen I. Trends in depression and anti-depressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One. 2012;7(3):e33181.CrossRefPubMedPubMedCentral
13.
Hammad TA. Review and evaluation of clinical data. BMJ. 2003;326(7402):1282. Available at http://​www.​fda.​gov/​ohrms/​dockets/​ac/​04/​briefing/​2004-4065b1-10-TAB08-Hammads-Review.​pdf (last accessed 24 April2014). Waechter F. Paroxetine must not be given to patients under 18.CrossRef
14.
Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet. 2004;363(9418):1341–5.CrossRef
15.
Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006;31(3):473–92. PubMed Epub 2005/12/02. eng.CrossRefPubMed
16.
17.
18.
Zito J, Safer D, Berg L, Janhsen K, Fegert J, Gardner J, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;25:26–32. doi:10.​1186/​1753-2000-2-26. PubMed PMID.CrossRef
19.
Gyllenberg D, Sourander A. Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study. Nord J Psychiatry. 2012;66(5):336–42. PubMed Epub 2012/01/04. eng.CrossRefPubMed
20.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011. ISBN: 978-82-8082-477-6.
21.
Hugtenburg JG, Heerdink ER, Egberts ACG. Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60(5):377–9. English.CrossRefPubMed
22.
Mittal M, Harrison DL, Miller MJ, Brahm NC. National anti-depressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning. Research in social & administrative pharmacy: RSAP. 2013 Nov 20. PubMed Epub 2013/12/21. Eng.
23.
Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Anti-depressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2013;22(8):511–8. English.CrossRefPubMed
24.
Volkers AC, Heerdink ER, van Dijk L. Anti-depressant use and off-label prescribing in children and adolescents in Dutch general practice (2001–2005). Pharmacoepidemiol Drug Saf. 2007;16(9):1054–62.CrossRefPubMed
25.
Parkinson K, Price J, Simon K, Tennyson S. The influence of FDA advisory information and black box warnings on individual use of prescription anti-depressants. Rev Econ Household. 2012 2012/05/15:1–20. English.
26.
Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand. 2014;129(3):221–31. PubMed Epub 2013/06/07. eng.CrossRefPubMed
27.
Pj C. TV: panaorama: “the secrets of seroxat”. BMJ. 2002.
28.
Jick H, Kaye JA, Jick SS. Anti-depressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338–43. PubMed Epub 2004/07/22. eng.CrossRefPubMed
29.
30.
Suicide trends among youths and young adults aged 10–24 years--United States, 1990–2004. MMWR Morbidity and mortality weekly report. 2007. 7;56(35):905–8. PubMed Epub 2007/09/07. Eng.
31.
Vitiello B. An international perspective on pediatric psychopharmacology1. Int Rev Psychiatry. 2008;20(2):121–6.CrossRefPubMed
Metadata
Title
Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning
Authors
K. O’Sullivan
F. Boland
U. Reulbach
N. Motterlini
D. Kelly
K. Bennett
T. Fahey
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2015
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-015-0436-2

Other articles of this Issue 1/2015

BMC Pediatrics 1/2015 Go to the issue

Research article

A clinically relevant method to screen for hepatic steatosis in overweight adolescents: a cross sectional study

Study protocol

PPREMO: a prospective cohort study of preterm infant brain structure and function to predict neurodevelopmental outcome

Research article

Neurodevelopmental outcome of extremely low birth weight infants at 24 months corrected age: a comparison between Griffiths and Bayley Scales

Research article

Measurement of delayed bathing and early initiation of breastfeeding: a cross-sectional survey exploring experiences of data collectors in Ethiopia

Research article

Prevalence of suspected developmental delays in early infancy: results from a regional population-based longitudinal study

Research article

Blood pressure tracking in urban black South African children: birth to twenty cohort